Dizhe Pharmaceutical: Notice on Convening the Second Extraordinary General Meeting of Shareholders in 2024
Dizal: Voluntary disclosure of the announcement regarding Gao Ruizhe (Golecitinib capsules) obtaining approval from the National Medical Products Administration for listing.
Dizal: Voluntary disclosure announcement on Schwarzer's first globally registered clinical study reaching a major research endpoint and oral report at the 2024 American Society of Clinical Oncology (ASCO) Conference
Dizal: Voluntary disclosure announcement on Schwarzer's latest research results being selected for the 2024 American Society of Clinical Oncology (ASCO) Conference Report
Dizal: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Dizal: Legal Opinion of Beijing Zhonglun Law Firm on the 2023 Annual General Meeting of Shareholders of Dighe (Jiangsu) Pharmaceutical Co., Ltd.
Dizal: 2023 Annual General Meeting of Shareholders Meeting Materials
Dizal: On promoting the 2024 “Improve Quality, Increase Efficiency, and Focus on Return” action plan
Dizal: Notice on convening the 2023 Annual General Meeting of Shareholders
Dizal: 2023 Internal Control Evaluation Report
Dizal: Report on the performance of the Audit Committee of the Board of Directors in 2023
Dizal: Special report of the board of directors on the self-inspection of the independence of independent directors
Dizal: PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) Special Report on the 2023 Non-Recurring Profit and Loss Statement of Digee (Jiangsu) Pharmaceutical Co., Ltd.
Dizhe Pharmaceutical: Voluntary disclosure of the announcement that Schwarzhe's first-line treatment for EGFR 20 exon insertion mutant advanced non-small cell lung cancer was recognized as a breakthrough treatment by the US FDA
Dizhe Pharmaceutical: Notice on changing the registered capital, revising the “Articles of Association”, and processing changes in industrial and commercial registration
Dizhe Pharmaceutical: Announcement of Resolutions of the 2024 First Extraordinary General Meeting of Shareholders
Legal Opinion of Beijing Zhonglun Law Firm on the 2024 First Extraordinary General Meeting of Shareholders of Dighe (Jiangsu) Pharmaceutical Co., Ltd.
Dizhe Pharmaceutical: 2024 First Extraordinary General Meeting of Shareholders Meeting Information
Dizhe Pharmaceutical: Notice on Convening the First Extraordinary General Meeting of Shareholders in 2024
Dizhe Pharmaceutical: Announcement on the results of the exercise of the third exercise period of the 2020 Employee Stock Option Plan and share changes
No Data